Scientists and Survivors
Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen
Bristol-Myers Squibb enters a worldwide collaboration with Janssen to develop and commercialize Bristol-Myers Squibb’s investigational Factor XIa inhibitor program.
Bristol-Myers Squibb Receives an FDA Approval
The most recent Bristol-Myers Squibb approval brings a new treatment option to certain patients with previously untreated advanced renal cell carcinoma.
Bristol-Myers Squibb and Nektar Therapeutics Enter Global Collaboration Agreement
The new $1.85 billion collaboration advances a strategic development partnership on a unique clinical-stage investigational immunotherapy agent.
Patients Are the Purpose
Each year, Bristol-Myers Squibb dedicates one week to recognize what its employees do every day: focus on patients.
Our R&D Team
Mike Quigley, Ph.D., Executive Director and Co-Lead, Immuno-Oncology Resistance Biology
AtlanticLIVE Series
AtlanticLIVE, underwritten by Bristol-Myers Squibb, is driving the conversations that address national cancer treatment challenges where they happen — in local communities.
2017 Annual Report
In every part of our organization and across the world, we are focused on the future. We are ready to provide patients with even more treatment options and even more hope. They are the reason we work harder and faster to deliver results.
Looking for Answers?
Quick links to helpful resources.